The expected five-year survival rate from a stage III ovarian cancer diagnosis is a mere 22%; this applies to the 7000 new cases diagnosed yearly in the UK. Stratification of patients with this heterogeneous disease, based on active molecular pathways, would aid a targeted treatment improving the prognosis for many cases. While hundreds of genes have been associated with ovarian cancer, few have yet been verified by peer research for clinical significance. Here, a meta-analysis approach was applied to two carefully selected gene expression microarray datasets. Artificial neural networks, Cox univariate survival analyses and T-tests identified genes whose expression was consistently and significantly associated with patient survival. The r...
Transcriptomic analysis of global gene expression in ovarian carcinoma can identify dysregulated gen...
BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ...
Ovarian cancer has a poor prognosis, with different outcomes for different patients. The mechanism u...
The expected five-year survival rate from a stage III ovarian cancer diagnosis is a mere 22%; this ...
The expected five-year survival rate from a stage III ovarian cancer diagnosis is a mere 22%; this a...
Abstract Background The five-year overall survival (OS) of advanced-stage ovarian cancer remains nea...
Gene expression provides rich information. Successful application has made to predict prognosis of s...
BACKGROUND: Public data integration may help overcome challenges in clinical implementation of micro...
Despite the existence of morphologically indistinguishable disease, patients with advanced ovarian t...
Ovarian cancer is the fifth-leading cause of cancer in women; afflicting 22,240 women in 2013 and an...
Ovarian carcinoma has the highest mortality rate among gynaecological malignancies. In this project,...
Ovarian cancer is the second most common gynecologic cancer and remains the leading cause of death o...
Abstract Background Ovarian cancer (OC) is a gynecological oncology that has a poor prognosis and hi...
Transcriptomic analysis of global gene expression in ovarian carcinoma can identify dysregulated gen...
Ovarian cancer is a heterogeneous disease with respect to histopathology, molecular biology, and cli...
Transcriptomic analysis of global gene expression in ovarian carcinoma can identify dysregulated gen...
BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ...
Ovarian cancer has a poor prognosis, with different outcomes for different patients. The mechanism u...
The expected five-year survival rate from a stage III ovarian cancer diagnosis is a mere 22%; this ...
The expected five-year survival rate from a stage III ovarian cancer diagnosis is a mere 22%; this a...
Abstract Background The five-year overall survival (OS) of advanced-stage ovarian cancer remains nea...
Gene expression provides rich information. Successful application has made to predict prognosis of s...
BACKGROUND: Public data integration may help overcome challenges in clinical implementation of micro...
Despite the existence of morphologically indistinguishable disease, patients with advanced ovarian t...
Ovarian cancer is the fifth-leading cause of cancer in women; afflicting 22,240 women in 2013 and an...
Ovarian carcinoma has the highest mortality rate among gynaecological malignancies. In this project,...
Ovarian cancer is the second most common gynecologic cancer and remains the leading cause of death o...
Abstract Background Ovarian cancer (OC) is a gynecological oncology that has a poor prognosis and hi...
Transcriptomic analysis of global gene expression in ovarian carcinoma can identify dysregulated gen...
Ovarian cancer is a heterogeneous disease with respect to histopathology, molecular biology, and cli...
Transcriptomic analysis of global gene expression in ovarian carcinoma can identify dysregulated gen...
BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ...
Ovarian cancer has a poor prognosis, with different outcomes for different patients. The mechanism u...